Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

4 Key Things Investors Should Know About Pfizer's Experimental COVID-19 Pill

TheMotleyFool

0 0

4 Key Things Investors Should Know About Pfizer's Experimental COVID-19 Pill

Merck (NYSE: MRK) has been in the spotlight recently with the announcement of positive results for its COVID-19 pill developed with Ridgeback Biotherapeutics. Pfizer (NYSE: PFE) is also evaluating an oral COVID-19 therapy and could be hot on the heels of Merck. In this Motley Fool Live video recorded on Sept. 29, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss four key things investors should know about Pfizer's experimental COVID-19 pill.

Source Fool.com

Like: 0

PFE

Share